Your shopping cart is currently empty

Ro 90-7501 is an amyloid β42 (Aβ42) protofibrillar and TPR-dependent PP5 inhibitor, a novel radiosensitizer for cervical cancer cells, which inhibits ATM phosphorylation, promotes apoptosis, and induces cell-cycle arrest. Ro 90-7501 also exhibits antiviral activity and potential anticancer activity by inhibiting ATM phosphorylation and DNA repair, and by inhibiting HCMV.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $30 | In Stock | In Stock | |
| 5 mg | $68 | In Stock | In Stock | |
| 10 mg | $123 | In Stock | In Stock | |
| 25 mg | $272 | In Stock | In Stock | |
| 50 mg | $463 | In Stock | In Stock | |
| 100 mg | $787 | In Stock | In Stock |
| Description | Ro 90-7501 is an amyloid β42 (Aβ42) protofibrillar and TPR-dependent PP5 inhibitor, a novel radiosensitizer for cervical cancer cells, which inhibits ATM phosphorylation, promotes apoptosis, and induces cell-cycle arrest. Ro 90-7501 also exhibits antiviral activity and potential anticancer activity by inhibiting ATM phosphorylation and DNA repair, and by inhibiting HCMV. |
| In vitro | Compared to control HeLa and ME-180 cells, Ro 90-7501 significantly enhances radiation sensitivity. Following irradiation, Ro 90-7501 markedly increases apoptosis and impairs the cell cycle. Post-irradiation, Ro 90-7501 suppresses the phosphorylation of ATM and its downstream proteins, such as H2AX, Chk1, and Chk2[2]. RO 90-7501 itself does not affect IFN-β and NFκB promoter activity but significantly enhances poly I:C-induced IFN-β promoter activation and dose-dependently inhibits NF-κB activation. Treatment with RO 90-7501 significantly enhances the antiviral activity of poly I:C[1]. |
| In vivo | Treatment with Ro 90-7501 (5 μg/g; intraperitoneal injection; daily; continuous for 21 days; female BALB/c nude mice) significantly delays tumor growth and markedly reduces tumor volume[2]. |
| Synonyms | RO-90-7501 |
| Molecular Weight | 340.38 |
| Formula | C20H16N6 |
| Cas No. | 293762-45-5 |
| Smiles | NC1=CC=C(C=C1)C1=NC2=C(N1)C=C(C=C2)C1=NC2=C(N1)C=C(N)C=C2 |
| Relative Density. | 1.443g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 30 mg/mL (88.14 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Saline: 2 mg/mL (5.88 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.